Original Article

Association between erectile dysfunction and coronary artery disease and it's severity

A. Sai Ravi Shankera,*, B. Phanikrishna b, C. Bhaktha Vatsala Reddyc

a Cardiologist, Department of Cardiology, Narayana Medical College, Chinta Reddy Palem, Narasaraopet 524003, Andhra Pradesh, India
b Associate Professor, Narayana Medical College, Chinta Reddy Palem, Narasaraopet 524003, Andhra Pradesh, India
c Assistant Professor, Narayana Medical College, Chinta Reddy Palem, Narasaraopet 524003, Andhra Pradesh, India

Abstract

Background/aims: To investigate the prevalence of erectile dysfunction (ED) in patients with coronary artery disease (CAD), the relationship between the severity of ED and the extent of coronary vessel involvement, and to register the mean time interval between them.

Methods: 240 patients with CAD divided into three age-matched groups: Group 1 (n = 60), ACS with one-vessel disease (1VD); group 2 (n = 60), ACS with 2,3VD; group 3 (n = 60), CSA. Control group (C, n = 60) was composed of patients with suspected CAD who were found to have entirely normal coronary arteries by angiography. ED as any value < 26 according to the Gensini's scores and according to the International Index of Erectile Function (IIEF).

Results: ED prevalence was 76%. ED prevalence was lower in G1 vs. G3 (22 vs. 65%). G2 ED rate [55%, P < 0.0001] IIEF = 24 (17–29) & Gensini's scores-21 (12.5–32) were significantly different from G1 and similar to G3, ED in ACS differs according to the extent of CAD. G3 patients who had ED symptoms prior to CAD symptoms and time interval between ED and CAD symptom onset in CCS according to number of vessels. Onset of sexual dysfunction occurred before CAD onset with a mean time interval of 24 m [12–36].

Conclusion: Early diagnosis of ED, cardiovascular assessment and aggressive treatment of cardiovascular risk factors might have contributed to prevent the acute events of this patient. Patients should be systematically screened for ED as a part of periodic examination programs. This would lead to early detection of modifiable vascular risk factors, or already existing vascular disease and to prevent ED and vascular disease progression through pharmacological and life style modifications.

Copyright © 2013, Cardiological Society of India. All rights reserved.
Erectile dysfunction is associated with significant changes in established cardiovascular risk factors such as fasting lipids, fasting glucose, body mass index (BMI), C-reactive protein (CRP) and homocysteine.20–23 Men with ED generally exhibit more severe CAD and left ventricular dysfunction than those without ED.24–26 and the severity of ED may also be correlated with the severity of CAD.27 It should be noted, however, that penile Doppler testing cannot be reliably used to identify at-risk men because of its average sensitivity and specificity, low positive predictive value and high negative predictive value.28 In around two-thirds of men, the onset of CAD is preceded by ED (Montorsi et al.). A number of studies have estimated the interval between the onset of ED symptoms and the occurrence of CAD symptoms to be 2–5 years, increasing to 21.1% in those aged 60–69 years. This compares with 4.3% and 16.6% in men without ED for the same age groups, i.e. an increase in relative risk of 1.14 and 1.27 respectively. The risk of experiencing a cardiovascular event at 3 years and a cardiovascular event at 5 years, although longer time frames have been reported.31

Using Framingham risk scores, the relative risk of developing CAD within 10 years in men with moderate-severe ED has been estimated as 4.9% in those aged 45–59 years, increasing to 21.1% in those aged 60–69 years. This compares with 4.3% and 16.6% in men without ED for the same age groups, i.e. an increase in relative risk of 1.14 and 1.27 respectively. The risk of experiencing a cardiovascular event within a 10-year timeframe was estimated by 1.3–1.6 times in men with ED vs. men without ED.

2. Aims and objectives of the study

To investigate the prevalence of ED in patients with CAD and to evaluate the relationship between the severity of ED and the extent of coronary vessel involvement and to register the first symptom and the mean time interval between them.

We tested the hypothesis that ED prevalence is related to coronary atherosclerotic burden that in turn is related to the type of clinical presentation—acute coronary syndrome (ACS) vs. chronic coronary syndrome (CCS). As atherosclerosis is a systemic disorder, penile circulation might be involved to a similarly different extent as coronary circulation in ACS vs. CCS patients. If true, ED prevalence should be low in the former and high in the latter.35,36

3. Methods

180 patients with CAD were divided into three age-matched groups: Group 1 (G1, n = 60), ACS with one-vessel disease (1-VD); Group 2 (G2, n = 60), ACS with two-vessel disease (2-VD); Group 3 (G3, n = 60), chronic stable angina. The control group (C, n = 60) was composed of patients with suspected CAD who were found to have entirely normal coronary arteries by angiography.

International Index of Erectile Function (IIEF) questionnaires were used to assess extent of ED. ED as any value <26 according to the global IIEF scores and according to the IIEF.

Between Dec 2010 and Nov 2011, 1630 patients underwent coronary angiography for both ACS and CCS syndromes at Nellore Medical college and Superspeciality hospital, Nellore, Andhra Pradesh. Two-hundred and two patients (12.4%) were found to have angiographically normal coronary arteries. Five-hundred and seventy (35%) were classified as ACS (first episode of acute ST-elevation myocardial infarction or non-ST elevation myocardial infarction or unstable angina),37 whereas the remaining patients were classified as CCS (defined as clinical and non-invasive evidence of stable myocardial ischemia lasting >2 months).

We have excluded:

1. Patients with previous percutaneous or surgical myocardial revascularization procedures.
2. Patients with diseases that could alter sexual activity, such as liver cirrhosis, renal failure, thyroid disease (hypo- and hyperthyroidism on replacement treatment), major depression on long-term pharmacological treatment, and spinal cord injuries, and those with previous pelvic, penile, urethral, or prostate trauma or surgery.
3. Patients with primary erectile dysfunction were excluded.

All patients underwent complete routine laboratory tests, included lipid profile, fasting glucose, and total and free-plasma testosterone levels. Diagnostic coronary angiography was carried out in all patients by the standard technique. If required, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery was carried out during the hospital stay. Risk factors (when not previously known) were defined according to the ESC/ACC/AHA guidelines as follows:38 hypertension as blood pressure >140/90 mmHg in three consecutive readings, at rest; hypercholesterolemia as total cholesterol level >200 mg/dL and/or LDL cholesterol level >130 mg/dL, diabetes as fasting glucose level >126 mg/dL; obesity as body mass index (BMI) >30 kg/m²; and family history of CAD as parents with CAD at age <55 (father) or <65 (mother).

Ankle-brachial index was taken as an accurate and reliable marker of generalized atherosclerosis. It was calculated by dividing the ankle systolic pressure by the brachial pressure (both measurements taken by cuff manometers). The lower of
the indexes obtained for the two legs was used as the measure of disease severity.\(^{42}\)

The Narayana medical college ethics committee approved the study protocol and each patient gave written informed consent.

IIEF-EFD questionnaire for ED (questions 1–5 and 15)

1. Q: how often were you able to get an erection during sexual activity? A: no sexual activity (0), almost never/never (1), a few times (much less than half of the time) (2), sometimes (about half of the time) (3), most times (much more than half the time) (4), almost always/always (5).

2. Q: when you had an erection with sexual stimulation, how often were your erections hard enough for penetration? A: no sexual activity (0), almost never/never (1), a few times (much less than half of the time) (2), sometimes (about half of the time) (3), most times (much more than half the time) (4), almost always/always (5).

3. Q: when you attempted sexual intercourse, how often were you able to penetrate your partner? A: no sexual activity (0), almost never/never (1), a few times (2), sometimes (about half of the time) (3), most times (much more than half the time) (4), almost always/always (5).

4. Q: during sexual intercourse, how difficult was it to maintain your erection after you had penetrated your partner? A: no sexual activity (0), almost never/never (1), a few times (2), sometimes (about half of the time) (3), most times (much more than half the time) (4), almost always/always (5).

5. Q: during sexual intercourse, how difficult were you able to maintain your erection to completion of intercourse? A: did not attempt intercourse (0), extremely difficult (1), very difficult (2), difficult (3), slightly difficult (4), not difficult (5).

6. Q: how do you rate your confidence that you could get and keep an erection? A: very low (1), low (2), moderate (3), high (4), very high (5)

3.1. Quantitative coronary angiography

Coronary angiography analysis was performed by the cardiologist who is unaware of the patient’s ED. IIEF-EFD questionnaire, using ARTREK Quantum I (Cardiowise Comm. System Inc, Sunnyvale, CA, USA).\(^{39}\) The outer diameter of the contrast-filled catheter was used for calibration. The lesions were analyzed in multiple projections, and reference vessel diameter, minimal lumen diameter, and percent diameter stenosis were measured from the ‘worst’ angiographic view. Significant angiographic narrowing was defined as >50% diameter stenosis involving either one major epicardial vessel at least of any collaterals with >0.3 mm diameter. Lesions were classified as having 1-VD, 2-VD, or 3-VD, if they had a single lesion in 1, 2, or 3 coronary vessels.

3.2. Gensini’s score

The method assigns a different severity score depending on the degree of stenosis, its location (proximal, middle or distal tract) along the target vessel and the type of coronary vessel involved (LAD, LCX or RCA) (Fig. 1).\(^{40}\)

3.3. Erectile function evaluation

Erectile function was evaluated by IIEF-EFD, a validated 15-item self-administered questionnaire.\(^{41}\) Erectile function is specifically addressed by six questions that form the so-called ‘erectile function domain’ of the questionnaire. Each question is scored 0 to 5. ED is defined as any value <26. In the case of ED, patient was asked to answer the following question: ‘Did ED symptoms come before CAD symptoms?’ If yes, how long before? (Months). IIEF questionnaire was administered to patients after a mean time interval of 3 [2–5] days since the admission to the hospital.

3.4. Statistical analysis

The relationship among ED prevalence, clinical presentation, and extension of CAD was analyzed by multivariable logistic regression adjusting for the following covariates: age; diabetes; hypertension; hypercholesterolemia; family history of CAD; smoking; BMI. Adjusted odds ratios (OR) and 95% CI were estimated. The area under the ROC curve was used as a measure of prediction ability. Data are presented as
mean ± SD, unless otherwise stated. A two tailed P-value <0.05 was considered as significant.

4. Results

One hundred and eighty patients with angiographically documented CAD were registered. Clinical characteristics of the study population are reported in (Table 1). There was no difference in age between groups. Risk factors were uniformly distributed between groups, except for smoking and diabetes that were significantly more frequent in G2 and G3 when compared with G1, respectively. Noteworthy, almost 50% of patients in each group had >3 risk factors. Overall ED prevalence was 47%. When separately considered, prevalence was 24%, 56%, and 64% in G1, G2, and G3, respectively (p < 0.0001 for G1 vs. G2 and G1 vs. G3; p < 0.45 for G2 vs. G3). ED prevalence in Controls was 22%. ED prevalence was lower (50% of patients in each group had >3 risk factors. Overall ED prevalence was 47%. When separately considered, prevalence was 24%, 56%, and 64% in G1, G2, and G3, respectively (p < 0.0001 for G1 vs. G2 and G1 vs. G3; p < 0.45 for G2 vs. G3). ED prevalence in Controls was 22%. ED prevalence was lower when compared with G1, respectively. Noteworthy, almost 50% of patients in each group had >3 risk factors. Overall ED prevalence was 47%. When separately considered, prevalence was 24%, 56%, and 64% in G1, G2, and G3, respectively (p < 0.0001 for G1 vs. G2 and G1 vs. G3; p < 0.45 for G2 vs. G3). A two tailed P-value <0.05 was considered as significant.

---

### Table 1 — Baseline characteristics with risk factors.

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Control (n = 60)</th>
<th>Gr-I (n = 60)</th>
<th>Gr-II (n = 60)</th>
<th>Gr-III (n = 60)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48.5 ± 9</td>
<td>52 ± 8.4</td>
<td>53 ± 8.3</td>
<td>55.4 ± 5.7</td>
<td>0.21</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.7 ± 1.2</td>
<td>26.9 ± 1.3</td>
<td>26.4 ± 1.3</td>
<td>26.9 ± 2.1</td>
<td>0.86</td>
</tr>
<tr>
<td>Symptom onset (months)</td>
<td>28 ± 12</td>
<td>22 ± 13</td>
<td>18 ± 12</td>
<td>16 ± 9</td>
<td>0.0008</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>57%</td>
<td>56%</td>
<td>54%</td>
<td>55%</td>
<td>0.13</td>
</tr>
<tr>
<td>Diabetes</td>
<td>15%</td>
<td>16%</td>
<td>32%</td>
<td>38%</td>
<td>0.06</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>61%</td>
<td>78%</td>
<td>76%</td>
<td>84%</td>
<td>0.06</td>
</tr>
<tr>
<td>Smoking</td>
<td>28%</td>
<td>45%</td>
<td>52%</td>
<td>58%</td>
<td>0.08</td>
</tr>
<tr>
<td>Obesity</td>
<td>12%</td>
<td>15%</td>
<td>21%</td>
<td>17%</td>
<td>0.07</td>
</tr>
<tr>
<td>F/H of CAD</td>
<td>6%</td>
<td>28%</td>
<td>38%</td>
<td>37%</td>
<td>0.0005</td>
</tr>
<tr>
<td>&gt;3 Risk factor</td>
<td>26%</td>
<td>42%</td>
<td>48%</td>
<td>42%</td>
<td>0.52</td>
</tr>
</tbody>
</table>

---

### Table 2 — Clinical characteristics of study population.

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Control (n = 60)</th>
<th>Gr-I (n = 60)</th>
<th>Gr-II (n = 60)</th>
<th>Gr-III (n = 60)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEMI</td>
<td>–</td>
<td>64%</td>
<td>68%</td>
<td>–</td>
<td>0.48</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>–</td>
<td>16%</td>
<td>15%</td>
<td>–</td>
<td>0.52</td>
</tr>
<tr>
<td>USA</td>
<td>–</td>
<td>20%</td>
<td>17%</td>
<td>–</td>
<td>0.12</td>
</tr>
<tr>
<td>CSA</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>ED prevalence</td>
<td>22%</td>
<td>24%</td>
<td>56%</td>
<td>64%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Involved coronary vessels, (n)</td>
<td>0</td>
<td>1 ± 0</td>
<td>2.2 ± 0.5</td>
<td>2.4 ± 0.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IIEF-EFD score</td>
<td>23 (20–26)</td>
<td>26 (24–28)</td>
<td>24 (18–29)</td>
<td>27 (26–29)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Modified Gensini’s score</td>
<td>0 (0–2)</td>
<td>4 (9–8)</td>
<td>22 (14–32)</td>
<td>42 (20–68)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time interval</td>
<td>12 (9–24)</td>
<td>14 (9–24)</td>
<td>24 (16–32)</td>
<td>34 (21–47)</td>
<td>0.016</td>
</tr>
<tr>
<td>Brachial-ankle index</td>
<td>1.12 ± 0.1</td>
<td>0.92 ± 0.1</td>
<td>0.90 ± 0.1</td>
<td>0.80 ± 0.3</td>
<td>0.001</td>
</tr>
</tbody>
</table>
5. Discussion

A significant proportion of men with ED exhibit early signs of CAD, and this group may develop more severe CAD than men without ED. Prevalence of ED differs across subsets of patients with CAD and is related to extent of CAD. In group I, ED prevalence was 24%. This value was similar to that obtained in age-matched controls with normal coronary arteries. Thus, most patients with ACS and 1-VD do not complain of ED as a result of an overall low coronary and penile atherosclerotic burden.

The finding that patients with CCS and 1-VD had higher ED rate (65 vs. 22%, p < 0.0001) when compared with patients with ACS and 1-VD, confirms the role of different pathophysiological background and related atherosclerotic burden at work in CCS (Fig. 3). Indeed, multivariate analysis showed that patients with CCS presentation had a 2.3-fold increase in relative risk of ED when compared with those with ACS, independent of other conventional risk factors. The lower ankle-brachial index (0.98 ± 0.10 vs. 0.80 ± 0.28, p < 0.0005), an accurate and reliable marker of generalized atherosclerosis, suggested a more advanced vascular involvement in CCS. The time interval between the onset of ED symptoms and the occurrence of CAD symptoms and cardiovascular events was estimated at 2–3 years and 3–5 years, respectively; this interval allows for risk factor reduction.

According to this finding, we evaluated whether ED may predict coronary artery involvement in ACS. Interestingly enough, this suggests that IIEF questionnaire may be a useful ‘bedside’ test to predict the extension of CAD in ACS: according to positive predictive value, even out of 10 patients with ED turned out to have angiographic multivessel disease.

ED-coronary atherosclerosis relationship by assessing ED rate according to CAD extension is being evaluated in this study. Interestingly enough, having 2- or 3-VD did not significantly increase ED prevalence as compared to 1-VD in both ACS and CCS patients with similar age (Fig. 2) suggesting ED as a sort of ‘on-off’ phenomenon that we hypothesized takes place when 0.50% angiographic obstruction of at least one major coronary vessel occurs. If true, having 2- or 3-VD would not add to ED prevalence. Almost 30% of patients with proved CAD did not complain of ED. Age may be an explanation. We are trying to be independent predictor of ED in the whole study patient population, with a 10% per patient increase in the yearly relative risk of ED. ED significantly increased over time being 30% under 50 years and close to 100% over 60 years of age. At any age ED rate was similar regardless extent of CAD, confirming the ‘on-off’ phenomenon.

We found that severe ED (a score < 10) was more frequent in patients with multi-vessel as compared to single-vessel disease (31 vs. 12.5%, p < 0.01). Moreover, IIEF-EFD score was significantly lower in the former than in the latter group and a significant inverse relationship between IIEF-EFD and modified Gensini’s score were found indicating more severe ED in patients with more diffuse coronary artery involvement.

Thus, severe ED in patients with stable CAD should raise questions about multi-vessel coronary involvement.

6. Conclusion

In the present study, ED prevalence was 24%. ED rate of control group was similar to that found in general population with no heart disease. Patients with CCS presentation had a 2.3-fold increase in relative risk of ED when compared with those with ACS. This suggests that the IIEF questionnaire may be a useful ‘bedside’ test to predict the extension of CAD. Severe ED (a score < 10) was more frequent in patients with multi-vessel as compared to single-vessel disease 0.83% of patients with CCS reported ED symptoms before angina pectoris onset, with a mean interval of 22 months heart disease.

The key findings of this study are (1) ED rate significantly differs across patients with established CAD according to coronary clinical presentation and atherosclerosis burden: it is low in ACS and 1-VD and high in CCS. (2) ED severity but not...
ED prevalence is related to extent of CAD. (3) ED symptoms
come prior to CAD symptoms in virtually all patients with a
mean time-interval of 3 years. (4) All men with ED should
undergo a thorough medical assessment, including testos-
terone, fasting lipids, fasting glucose and blood pressure
measurement. (5) Following assessment, patients should be
stratified according to the risk of future cardiovascular events.
(6) Those at high risk of cardiovascular disease should be
evaluated by stress testing with selective use of computed
tomography (CT) or coronary angiography. (7) Improvement in
vascular symptoms and exercise tolerance should be estab-
lished prior to initiation of ED therapy. (10) Clinical evidence
supports the use of phosphodiesterase 5 (PDE5) inhibitors as
primary treatment. (8) In men with ED, hypertension, diabetes and hyper-
lipidemia should be treated aggressively, bearing in mind the
potential side effects. (9) Management of ED is secondary to
lipidemia should be treated aggressively, bearing in mind the
prevention of future cardiovascular events. (4) All men with ED should
undergo a thorough medical assessment, including testos-
terone, fasting lipids, fasting glucose and blood pressure
measurement. (5) Following assessment, patients should be
stratified according to the risk of future cardiovascular events.
(6) Those at high risk of cardiovascular disease should be
evaluated by stress testing with selective use of computed
tomography (CT) or coronary angiography. (7) Improvement in
vascular symptoms and exercise tolerance should be estab-
lished prior to initiation of ED therapy. (10) Clinical evidence
supports the use of phosphodiesterase 5 (PDE5) inhibitors as
primary treatment. (8) In men with ED, hypertension, diabetes and hyper-
lipidemia should be treated aggressively, bearing in mind the
potential side effects. (9) Management of ED is secondary to
lipidemia should be treated aggressively, bearing in mind the
PREVIOUSLY RETRACTED

**Conflicts of interest**

All authors have none to declare.

**References**

2. Aytac IA, McKinlay JB, Krane RJ. The like to blood vessel
in erectile dysfunction between 1995 and 2025 and some